Lexaria Bioscience Corp. (LEXX) stock
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
$4.18−0.23 (-5.22%)
Close on Nov 17, 2026Market cap $103.61MP/E –Yield –
Lexaria Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Lexaria Bioscience's R&D Expenses for the twelve months ending May 31, 2026 was $4.00M, down 45.4% year over year. For fiscal 2025 it was $8.24M, up 249.0% from the year before. Over ten years it grew 49.6% a year on average. The highest annual figure on record is $8.24M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $8.24M | +249.0% |
| FY2024 | Aug 31, 2024 | $2.36M | -35.6% |
| FY2023 | Aug 31, 2023 | $3.67M | +99.0% |
| FY2022 | Aug 31, 2022 | $1.84M | +45.9% |
| FY2021 | Aug 31, 2021 | $1.26M | +226.3% |
| FY2020 | Aug 31, 2020 | $387.07K | -30.3% |
| FY2019 | Aug 31, 2019 | $555.73K | +12.8% |
| FY2018 | Aug 31, 2018 | $492.86K | +809.6% |
| FY2017 | Aug 31, 2017 | $54.19K | +500.5% |
| FY2016 | Aug 31, 2016 | $9.02K | -93.8% |
| FY2015 | Aug 31, 2015 | $146.47K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | $970.83K | -64.3% |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | $475.39K | -71.8% |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | $671.34K | -65.6% |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | $1.88M | +94.6% |
| Q3 FY2025CQ2 2025 | May 31, 2025 | $2.72M | +374.2% |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | $1.69M | +585.9% |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | $1.95M | +240.0% |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | $967.21K | +93.3% |
| Q3 FY2024CQ2 2024 | May 31, 2024 | $573.09K | -65.1% |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | $245.78K | -64.7% |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | $574.49K | -30.7% |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | $500.41K | +40.5% |
| Q3 FY2023CQ2 2023 | May 31, 2023 | $1.64M | +118.1% |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | $696.18K | +152.5% |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | $829.49K | +80.8% |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | $356.19K | -19.0% |
| Q3 FY2022CQ2 2022 | May 31, 2022 | $752.10K | +65.5% |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | $275.69K | +56.3% |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | $458.71K | +138.6% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $439.79K | +542.1% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $454.44K | +1750.6% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $176.40K | -5.4% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $192.26K | +78.9% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $68.50K | -57.6% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $24.56K | -89.4% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $186.56K | +182.3% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $107.46K | +10.8% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $161.64K | -24.3% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $231.04K | +148.2% |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | $66.08K | -12.8% |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | $96.97K | -12.2% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $213.64K | +591.3% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $93.07K | +1029.5% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $75.76K | +874.1% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $110.39K | +1420.3% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $30.91K | +83429.7% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $8.24K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $7.78K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $7.26K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $37 | – |
See a number that looks wrong?